Pharmaceutical advertising compliance

Pharmaceutical advertising compliance sits at an unusual intersection for Financial & Capital Markets firms: investor communications, sponsored content, and health-sector marketing campaigns can all trigger scrutiny from the U.S. Food and Drug Administration's Office of Prescription Drug Promotion and the U.S. Federal Trade Commission, particularly where pharma-linked investment products or co-branded health initiatives blur the line between promotion and disclosure. The U.S. Securities and Exchange Commission has also flagged material omissions in sector-specific marketing as a recurring enforcement pattern, especially for funds with concentrated biotech or pharmaceutical holdings. Compliance teams at broker-dealers and asset managers are currently mapping their pharma-sector marketing materials against FTC's updated endorsement guides (revised 2023) and SEC's advertising rule amendments under Rule 206(4)-1.